Vulvar Cancer - Pipeline Review, H1 2018

May 2018 | 125 pages | ID: VE71D16E2C1EN
Global Markets Direct

Abstracts

Vulvar Cancer - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vulvar Cancer - Pipeline Review, H1 2018, provides an overview of the Vulvar Cancer (Oncology) pipeline landscape.

Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vulvar Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Vulvar Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vulvar Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 7 and 2 respectively.

Vulvar Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Vulvar Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Vulvar Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Vulvar Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Vulvar Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Vulvar Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Vulvar Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Vulvar Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Vulvar Cancer - Overview
Vulvar Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Vulvar Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vulvar Cancer - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Cutanea Life Sciences Inc
IRX Therapeutics Inc
ISA Pharmaceuticals BV
MedImmune LLC
Merck KGaA
Ono Pharmaceutical Co Ltd
Transgene SA
Vulvar Cancer - Drug Profiles
ABI-1968 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
durvalumab + tremelimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ipilimumab + nivolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IRX-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISA-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-7824 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nivolumab - Drug Profile
Mechanism Of Action
R&D Progress
omiganan pentahydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TG-4001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vulvar Cancer - Dormant Projects
Vulvar Cancer - Product Development Milestones
Featured News & Press Releases
Oct 05, 2011: FDA Grants ISA Pharmaceuticals Orphan Drug Designation For Treatment Of Vulvar Intraepithelial Neoplasia With ISA-HPV-SLP
Mar 07, 2011: ISA Pharma Receives €2.7m From Dutch Government To Further Clinical Development Of HPV-SLP Vaccine
Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials
Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Vulvar Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Vulvar Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018
Vulvar Cancer - Pipeline by Cutanea Life Sciences Inc, H1 2018
Vulvar Cancer - Pipeline by IRX Therapeutics Inc, H1 2018
Vulvar Cancer - Pipeline by ISA Pharmaceuticals BV, H1 2018
Vulvar Cancer - Pipeline by MedImmune LLC, H1 2018
Vulvar Cancer - Pipeline by Merck KGaA, H1 2018
Vulvar Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018
Vulvar Cancer - Pipeline by Transgene SA, H1 2018
Vulvar Cancer - Dormant Projects, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Vulvar Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Bristol-Myers Squibb Co
Cutanea Life Sciences Inc
IRX Therapeutics Inc
ISA Pharmaceuticals BV
MedImmune LLC
Merck KGaA
Ono Pharmaceutical Co Ltd
Transgene SA